Wildemeersch Dirk
a Gynecological Outpatient Clinic and IUD Training Center - Drug Delivery Research in Women's Health , Ghent , Belgium.
Gynecol Endocrinol. 2016 Aug;32(8):659-661. doi: 10.3109/09513590.2016.1153056. Epub 2016 Mar 1.
The use of a levonorgestrel intrauterine system (LNG-IUS) is useful in preventing pregnancy and for the treatment of menstrual disturbances. A smooth or symptom-free transition to and through menopause is possible when LNG-IUS is combined with estrogen therapy. Unfortunately the majority of physicians are generally unaware of this usefulness combined hormonal therapy in the pre-, peri- and postmenopausal women.
Based on long-term clinical experience with LNG-IUS in the form of Femilis®, 104 women where followed from the premenopause through the menopausal transition into the postmenopause. These perimenopausal women received supplemental 17 β-estradiol by gel or patch, or orally as estradiol valerate. Patients received one or two separate Femilis insertions at 5 year intervals. Main outcome measures included acceptability and continued use of the combined regimen for the treatment of climacteric symptoms and for prevention of cardiovascular disease, osteoporosis and other adverse effects caused by estrogen deprivation.
The average age at insertion was 48 years (range 28-58) and the total duration of use was 137 months (range 80-161). The Femilis LNG-IUS was well tolerated as the number of removals for LNG-IUS-related reasons was low. The LNG-IUS was well retained in the uterine cavity as no expulsions were observed. Seven women were lost to follow-up. Eighty-six women (82%) opted for replacement of an LNG-IUS at expiry after 5 years and continued with the estrogen therapy.
Intrauterine progestogen delivery for endometrial suppression in combination with estrogen therapy in the symptomatic perimenopausal women is highly practical as it combines the benefits of prevention of endometrial proliferation and treatment of menorrhagia and hyperplasia, if present. In addition, the contraceptive effect of locally administered LNG is highly desirable as many perimenopausal women run considerable risk of unintended pregnancy. For these reasons, the author views this regimen as one of the most effective, safest and best accepted route resulting in high patient compliance. It is important to convey this message to general practitioners as well as women.
左炔诺孕酮宫内节育系统(LNG-IUS)可用于预防妊娠及治疗月经紊乱。当LNG-IUS与雌激素疗法联合使用时,可实现平稳或无症状地过渡到更年期及度过更年期。不幸的是,大多数医生通常并未意识到这种联合激素疗法对绝经前、围绝经期和绝经后女性的益处。
基于Femilis®形式的LNG-IUS的长期临床经验,对104名女性进行了从绝经前到绝经过渡再到绝经后的随访。这些围绝经期女性通过凝胶、贴片或口服戊酸雌二醇接受补充17β-雌二醇。患者每隔5年接受一次或两次单独的Femilis植入。主要结局指标包括联合治疗方案用于治疗更年期症状以及预防心血管疾病、骨质疏松症和雌激素缺乏引起的其他不良反应的可接受性和持续使用情况。
植入时的平均年龄为48岁(范围28 - 58岁),总使用时长为137个月(范围80 - 161个月)。Femilis LNG-IUS耐受性良好,因与LNG-IUS相关原因取出的数量较少。LNG-IUS在子宫腔内保留良好,未观察到排出情况。7名女性失访。86名女性(82%)在5年后到期时选择更换LNG-IUS并继续接受雌激素治疗。
对于有症状的围绝经期女性,宫内孕激素给药以抑制子宫内膜并联合雌激素疗法非常实用,因为它兼具预防子宫内膜增生以及治疗月经过多和增生(如有)的益处。此外,局部给药LNG的避孕效果非常理想,因为许多围绝经期女性意外怀孕的风险相当高。出于这些原因,作者认为该方案是最有效、最安全且最易被接受的途径之一,能带来较高的患者依从性。将此信息传达给全科医生以及女性非常重要。